Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | KCNJ1 | P48048 | 3/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | GPR6 | P46095 | 4/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 2/20 | 0.32 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.32 |
| ▸ | GLP1R | P43220 | 1/20 | 0.32 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28786573 | 0.86 | HRH3 (0.42) | CNR1HRH3 | |
| SCHEMBL28754410 | 0.77 | EGLN2 (0.37) | — | |
| SCHEMBL22391829 | 0.75 | PKM (0.34) | — | |
| SCHEMBL28786609 | 0.75 | L3MBTL1 (0.39) | CYP11B1 | |
| SCHEMBL22528074 | 0.72 | GLP1R (0.52) | GLP1R | |
| SCHEMBL29390055 | 0.72 | GLP1R (0.52) | GLP1R | |
| Hydrochloric Acid SCHEMBL28944814 | 0.69 | IKBKB (0.36) | CYP11B1CYP11B2 | |
| SCHEMBL28754383 | 0.67 | EGLN2 (0.35) | — | |
| SCHEMBL4883141 | 0.66 | ALOX5 (0.49) | — | |
| SCHEMBL22391810 | 0.65 | CYP11B2 (0.34) | CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278991-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2023-09-07 | — | — | US | disclosed |
| US-11591321-B2 | GLP-1R agonists and uses thereof | QILU REGOR THERAPEUTICS INC. (CN) | 2023-02-28 | — | — | US | disclosed |
| US-20210179594-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2021-06-17 | — | — | US | disclosed |
| US-10954221-B2 | GLP-1R agonists and uses thereof | QILU REGOR THERAPEUTICS INC. (CN) | 2021-03-23 | — | — | US | disclosed |
| US-20200325121-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2020-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591321-B2 | GLP-1R agonists and uses thereof | GLP1R, GPR119, GIPR | LRRK2 1311/4885CNR1 495/4885KCNJ1 1960/4885 |
| US-10954221-B2 | GLP-1R agonists and uses thereof | GLP1R, GPR119, GIPR | LRRK2 1253/4885CNR1 411/4885KCNJ1 1990/4885 |
| US-20230278991-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | LRRK2 1253/4885CNR1 411/4885KCNJ1 1990/4885 |
| US-20200325121-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | LRRK2 1253/4885CNR1 411/4885KCNJ1 1990/4885 |
| US-20210179594-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | LRRK2 1253/4885CNR1 411/4885KCNJ1 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.